<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A few observational studies have shown the protective effect of <z:chebi fb="0" ids="35664">statins</z:chebi> on preventing <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, the disparate study results prompt further exploration of this concept </plain></SENT>
<SENT sid="2" pm="."><plain>We performed a meta-analysis to assess whether <z:chebi fb="0" ids="35664">statin</z:chebi> therapy is associated with a decrease in the incidence or recurrence of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> in patients with an implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>).The MEDLINE(Â®) and Cochrane databases were searched from 1980 to July 2009 for studies examining the effect of <z:chebi fb="0" ids="35664">statins</z:chebi> on VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> in recipients of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We retrieved <z:hpo ids='HP_0000001'>all</z:hpo> prospective cohort studies that examined this association </plain></SENT>
<SENT sid="4" pm="."><plain>The endpoint was defined as appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy for VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The quality of individual studies was assessed using the Newcastle Ottawa Scale.Seven prospective cohort studies met our inclusion criteria with a total of 2278 patients with a mean follow-up of 19.7 months </plain></SENT>
<SENT sid="6" pm="."><plain>Pooled analysis of the eligible studies revealed that <z:chebi fb="0" ids="35664">statin</z:chebi> therapy was associated with a 45% reduction in the risk of developing VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> in recepients of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> [pooled odds ratio (pOR): 0.55; 95% confidence interval: 0.34-0.90; <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> I(2) = 81%, P = 0.02] </plain></SENT>
<SENT sid="7" pm="."><plain>In a subgroup analysis, the magnitude of the risk reduction in patients with ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> was 54% (pOR: 0.46, P = 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Sensitivity analysis including studies with higher methodological qualities alone showed a significant protective effect (pOR: 0.48, P = 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>There was no evidence of publication bias in the analysis.Our meta-analysis suggests an association between the use of <z:chebi fb="0" ids="35664">statin</z:chebi> and a reduction in the VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> occurrence in recipients of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>, mainly in patients with ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
</text></document>